Core Insights - The 2025 China Biotechnology Innovation Conference was held in Chengdu High-tech Zone, showcasing the region's strong innovation vitality and leadership in the biopharmaceutical industry, ranking fourth in the 2024 China Biopharmaceutical Industry Park Annual Competitiveness Ranking [1] Group 1: Innovation Platforms - Chengdu High-tech Zone established the "Global New Drug Discovery Center" to foster original scientific achievements and leading talents, addressing challenges in drug development by integrating resources and promoting collaboration [2] - The region has developed multiple high-level innovation platforms, including the National Precision Medicine Industry Innovation Center and Tianfu Jincheng Laboratory, to enhance source innovation and result transformation capabilities [2] Group 2: Industry Growth - Chengdu High-tech Zone has attracted over 3,000 biopharmaceutical companies and established more than 160 functional platforms, with over 300 projects introduced and a total investment exceeding 120 billion yuan [3] Group 3: Policy and Financial Support - The region has implemented comprehensive policies to support the biopharmaceutical industry, focusing on strategic construction, innovation enhancement, and ecosystem development [4] - Chengdu High-tech Zone has created a six-in-one capital support system, forming 25 funds with a total scale of 35.2 billion yuan, and introduced unique financial products like "Bio Loan" to alleviate funding bottlenecks for innovative enterprises [5] Group 4: Future Outlook - Chengdu High-tech Zone aims to continue gathering global innovation resources and deepen the integration of industry, academia, and research, contributing significantly to the development of China's biopharmaceutical industry [6]

Group 1 - The core agreement between Chengdu High-tech Zone and Sichuan Development (Holding) Company focuses on deep cooperation in the pharmaceutical and health industry, including equity cooperation, fund establishment, talent exchange, and innovation incubation [2] - The collaboration aims to enhance the pharmaceutical health industry in Sichuan Province by building industrial funds, attracting quality projects, and developing professional incubation platforms [2][3] - Chengdu High-tech Zone is recognized as a key area for developing new productive forces, particularly in the pharmaceutical health sector, with plans to strengthen industrial cooperation in biomedicine [2] Group 2 - Since 2022, Chengdu High-tech Zone has been collaborating with Sichuan Development (Holding) Company's subsidiary, Sichuan Biopharmaceutical Group, focusing on investment in chemical drugs, medical devices, and pharmaceutical outsourcing services [3] - The partnership has successfully completed acquisitions, such as Sichuan Biopharmaceutical Group's acquisition of Hongming Bosi Pharmaceutical, and has nurtured several listed companies and local star enterprises [3] - Chengdu High-tech Zone has gathered over 3,900 biopharmaceutical companies and established more than 160 functional platforms covering the entire lifecycle of biopharmaceuticals [4] Group 3 - The capital support service system in Chengdu High-tech Zone includes a full lifecycle model with 24 pharmaceutical health funds totaling 34 billion yuan [4] - The zone has approved 12 Class I new drugs and over 100 Class III medical devices, with more than 80 products valued at over 100 million yuan [4] - Chengdu High-tech Zone has maintained a leading position in the national biopharmaceutical industrial park competitiveness ranking for several years [4]

Core Viewpoint - Chengdu High-tech Zone is enhancing its business environment for the biopharmaceutical industry through the "Wutong Plan," which provides a full lifecycle service system to support companies from inception to growth [2][10]. Group 1: Financing and Investment - Zeling Bio completed nearly 400 million yuan in B+ round financing, and Weijin secured a strategic cooperation deal worth 1.1 billion yuan [2]. - Chengdu High-tech Zone is addressing the financing challenges of biopharmaceutical companies with tailored financial products like "Bio loans" for different development stages [9]. Group 2: Service Efficiency and Approval Processes - The "Wutong Plan" includes a comprehensive service guide that streamlines the approval process, reducing the time from land acquisition to construction permit to as short as 3 working days [3][5]. - The Chengdu Tianfu International Biotech City has integrated over 40 service guidelines into a single approval process, shortening project preparation time by an average of 45% [5]. Group 3: Customized Services - The High-tech Zone is shifting from a generalized service approach to a customized service model, addressing specific needs of biopharmaceutical companies at various growth stages [7]. - The introduction of a "one-stop" service model allows companies to complete registration in as little as 1 working day, significantly faster than the industry average [6]. Group 4: Ecosystem Development - The "Wutong Plan" connects nine service sectors, creating a self-sustaining ecosystem that supports companies throughout their lifecycle, from research and development to commercialization [10]. - Chengdu High-tech Zone has established over 160 functional platforms for biopharmaceuticals, with 12 new drugs launched and over 120 in clinical research [12][13].